Cipla receives final approval for generic version of Sunovion Pharmaceuticals, Inc.’s Brovana

Brovana® is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Cipla Limited today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA).

Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana.

Brovana® is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for:

Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

According to IQVIA (IMS Health), Brovana had US sales of approximately $438M for the 12-month period ending April 2021.

The product is available for shipping immediately.

Tags : #LatestCiplaNewsJune23 #LatestPharmaNewsJune23 #TreatmentforBronchoconstruction #TreatmentforCOPD

About the Author


Sana Farid Khan

“The best way to become acquainted with a subject is to write about it."
A confident counselor, a speaker, and an educator, ready to utilize my communication skills effectively in the world of healthcare by putting pen to paper to reach new heights of success.
You can write to me at [email protected]

Related Stories

Loading Please wait...